

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 9, 2006

Signature:

  
(Lenay Rogus)

Patent

Docket No. 514572002000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ze LI et al.

Serial No.: 10/564,378

Filing Date (Int'l): July 14, 2003

For: METHODS AND COMPOSITIONS FOR  
DETECTING SARS VIRUS AND  
OTHER INFECTIOUS AGENTS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 27 and 28 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on June 10, 2004, directed to a counterpart international or foreign application and have not been previously cited.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;  
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 514572002000.

Dated: March 8, 2006

Respectfully submitted,

By   
Peng Chen  
Registration No.: 43,543  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive  
Suite 100  
San Diego, California 92130-2040  
(858) 720-5117

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/564,378
				Filing Date	(Int'l) July 14, 2003
				First Named Inventor	Ze LI
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	514572002000

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-4,134,792	01-16-1979	Boguslaski et al.	
	2.	US-4,230,797	10-28-1980	Boguslaski et al.	
	3.	US-4,238,565	12-09-1980	Hornby et al.	
	4.	US-4,683,195	07-28-1987	Mullis et al.	
	5.	US-4,683,202	07-28-1987	Mullis	
	6.	US-4,800,159	01-24-1989	Mullis et al.	
	7.	US-4,965,188	10-23-1990	Mullis et al.	
	8.	US-5,119,801	06-09-1992	Eizenhoefer et al.	
	9.	US-5,130,238	07-14-1992	Malek et al.	
	10.	US-5,143,854	09-01-1992	Pirrung et al.	
	11.	US-5,270,184	12-14-1993	Walker et al.	
	12.	US-5,288,514	02-22-1994	Ellman	
	13.	US-5,312,233	05-17-1994	Tanny et al.	
	14.	US-5,312,728	05-17-1994	Lizardi et al.	
	15.	US-5,348,855	09-20-1994	Dattagupta et al.	
	16.	US-5,384,261	01-24-1995	Winkler et al.	
	17.	US-5,541,061	07-30-1996	Fodor et al.	
	18.	US-5,556,752	09-17-1996	Lockhart et al.	
	19.	US-5,561,071	10-01-1996	Hollenberg et al.	
	20.	US-5,648,211	07-15-1997	Fraiser et al.	
	21.	US-5,677,195	10-14-1997	Winkler et al.	
	22.	US-6,004,745	12-21-1999	Arnold, Jr. et al.	
	23.	US-6,024,138	02-15-2000	Fritz et al.	
	24.	US-6,150,097	11-21-2000	Tyagi et al.	
	25.	US-6,156,508	12-05-2000	Spears et al.	
	26.	US-6,300,076	10-09-2001	Koster	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	27.	CN-1469126	01-21-2004		
	28.	CN-1472342	02-04-2004		
	29.	EP-0 684 315	11-29-1995		
	30.	GB-1,548,741	07-18-1979		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd-299103

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/564,378	
			Filing Date	(Int'l) July 14, 2003	
			First Named Inventor	Ze LI	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	514572002000

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	31.	BOOTH et al., JAMA (2003) 289:2801-2809		
	32.	BROUDE et al., Nucleic Acids Res. (2001) 29(19):E92		
	33.	DATTAGUPTA et al., Analytical Biochemistry (1989) 177:85-89		
	34.	DE PAULA et al., J. Virol. Methods (2001) 98(2):119-125		
	35.	FORSTER et al., Nucleic Acid Res. (1985) 13:745		
	36.	GenBank Accession No. AJ441252		
	37.	GenBank Accession No. AY278488		
	38.	GenBank Accession No. AY278487		
	39.	GenBank Accession No. AY278490		
	40.	GenBank Accession No. AY278489		
	41.	GenBank Accession No. AY279354		
	42.	GenBank Accession No. AY278554		
	43.	GenBank Accession No. AY278491		
	44.	GenBank Accession No. AY278741		
	45.	GenBank Accession No. AY274119		
	46.	GenBank Accession No. NC 004718		
	47.	GenBank Accession No. NM 002046		
	48.	GORUS and SCHRAM, Clin. Chem. (1979) 25:512-519		
	49.	GRAVITT et al., J. Clin. Micro. (1998) 36:3020-3027		
	50.	HERTZBERG et al., J. Amer. Chem. Soc. (1982) 104:313		
	51.	International Search Report for PCT/CN03/00561, mailed on June 10, 2004, 1 page		
	52.	KWOH et al., PNAS USA (1989) 86:1173-1177		
	53.	MARRA et al., The Genome Sequence of the SARS-Associated Coronavirus, Science, May 1, 2003, published online at www.sciencexpress.org		
	54.	MATTEUCCI et al., J. Am. Chem. Soc. (1981) 3:3185-3191		
	55.	MILLIGAN et al., J. Med. Chem. (1993) 36:1923-1937		
	56.	MITCHELL et al., J. Am. Chem. Soc. (1982) 104:4265		
	57.	ROTA et al., Science (2003) 300(5624):1394-1399		
	58.	SAIKI et al., PNAS USA (1989) 86:6230-6234		
	59.	SHAW et al., Nucleic Acids Res. (1991) 19:747		
	60.	SOINI and HEMMILA, Clin. Chem. (1979) 25:353		
	61.	TYAGI and KRAMER, Nature Biotech. (1996) 14:303-309		
	62.	WANG et al., PNAS USA (2002) 99(24):15687-15692		
	63.	WHITE et al., Meth. Enzymol. (1977) 46:644		
	64.	WHITEHEAD et al., Clin. Chem. (1979) 25:1531-1546		
	65.	WISDOM, Clin. Chem. (1976) 22:1243		
	66.	WOOD et al., PNAS USA (1985) 82:1585-1588		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd-299103